The FDA approved an additional indication for pembrolizumab (Keytruda, Merck)—monotherapy for locally advanced cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
In June 2020, pembrolizumab was approved as monotherapy for the treatment of patients with recurrent or metastatic cSCC that is not curable by surgery or radiation.
The latest approval is based on data from the second interim analysis of the multicohort, nonrandomized, open-label,